By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Response Biomedical said on Wednesday that it has closed on a previously announced C$8 million ($7.7 million) private placement.

More than 13.3 million shares in aggregate were placed to Caduceus Private Investments III, OrbiMed Associates III, and Caduceus Asia Partners, all affiliates of OrbiMed Advisors. Each share was priced at C$0.60.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.